ÓSKARE CAPITAL QUARTERLY NEWSLETTER

APRIL 2021

Full Newsletter via following link: Oskare Capital – Newsletter – April 2021

OUR LATEST NEWS:

Óskare Capital Webinar – The Endocannabinoid System

Óskare Capital’s First Portfolio Company, Octarine Bio, Raises $3 Million USD

Guest Post: The Symbiosis of Regulation and Science – Óskare Capital SAS

ÓSKARE CAPITAL STRENGTHENS TEAM AND EXTENDS COVERAGE TO THE AMERICAS BY WELCOMING JD WECHSLER AS VENTURE PARTNER

Guest Post: The Cannabis Conversation with Anuj Desai – Interview with Alex Ouimet-Storrs and Bruce Linton of Óskare Capital

ÓSKARE CAPITAL STRENGTHENS TEAM WITH TWO NEW MEMBERS

Home
About
Team
Investments
News
ESG
Contact
Regulatory Information

ÓSKARE CAPITAL

Société par actions simplifiée
au capital de 100 000€
RCS Paris 880 430 582
154 RUE DE LOURMEL 75015 PARIS

CONTACT INFO

Phone: +33 (0) 6 68 29 57 94
Email : alex@oskarecapital.com

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

HOME

ABOUT

TEAM

INVESTMENTS

MEDIA

ESG

CONTACT

REGULATORY INFORMATION

Our latest news

Óskare Capital Webinar – The Endocannabinoid System

Óskare Capital’s First Portfolio Company, Octarine Bio, Raises $3 Million USD

Guest Post: The Symbiosis of Regulation and Science – Óskare Capital SAS

ÓSKARE CAPITAL

CONTACT INFO